Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Antibody Fragments Market from 2024 to 2025?
The market size for antibody fragments has experienced significant growth in the past few years. It’s projected to escalate from $10.35 billion in 2024 to $11.37 billion in 2025, at a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this growth in the historic period include a surge in chronic diseases, the burgeoning adoption of biologics, an upsurge in cancer therapeutics, regulatory sanctions for antibody-centric treatment, and the augmentation of biopharmaceutical research.
What Is the Projected Market Size of the Antibody Fragments Market?
The market for antibody fragments is projected to undergo robust expansion in the coming years. It is anticipated to inflate to $16.44 billion by 2029, experiencing a compound annual growth rate (CAGR) of 9.6%. This growth during the forecast period can be credited to an uptick in biologics’ research and development investment, a burgeoning inclination towards smaller antibody formats, escalating demand for personalized medicine, wider use in the treatment of autoimmune diseases, and the advent of bispecific antibodies. Significant trends encompassing the prediction interval comprise the synergy of AI-oriented drug discovery, devising economical production techniques, strategic alliances amongst biotech companies, breakthroughs in monoclonal antibody technology, and emphasis on antibody-drug conjugates.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23307&type=smp
Who are the Major Competitors in the Antibody Fragments Market Outlook?
Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.
What Is Fueling Growth in the Antibody Fragments Market?
The rise in specific diseases known as target diseases is expected to drive growth in the antibody fragments market. Target diseases, defined as distinct health issues or illnesses that a particular medical research, treatment or medication aims to control, cure, or prevent, majorly include cancer, bacterial infections, and infectious diseases. The rise of target diseases can mainly be attributed to poor lifestyles and the weakening of the body’s defense system due to pollution, leading to chronic diseases. Antibody fragments offer highly targeted, specific, and adaptable treatment alternatives for different diseases, usually with fewer side effects compared to traditional treatments. They have the unique ability to be tailored and engineered for specific targets, positioning them as a key resource in contemporary medicine. For example, a report released by the American Cancer Society, a non-profit organization based in the US, forecasts 2,041,910 new cancer cases and 618,120 cancer deaths in the United States in January 2025, a rise from 2,001,140 new cases, and 611,720 deaths in 2024. As such, the escalating prevalence of target diseases stimulates the expansion of the antibody fragments market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23307&type=smp
Which Antibody Fragments Market Segments Are Growing the Fastest?
The antibody fragments market covered in this report is segmented –
1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types
2) By Specificity: Monoclonal Antibody, Polyclonal Antibody
3) By Delivery Method: Intravenous (IV), Subcutaneous (SC), Oral, Transdermal
4) By Application: Cancer, Immunodeficiencies, Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs)
Subsegments:
1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments
2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments
3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs)
4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs)
5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments
Which Industry Trends Are Shaping the Future of the Antibody Fragments Market?
Major firms engaged in the antibody fragments market are prioritizing clinical trials to create novel products, like human VH antibody fragments. These advancements aim to boost the efficiency of targeted treatments and minimize immunogenicity when combating cancers, autoimmune diseases, and infectious disorders. A human VH antibody fragment, the variable domain of a human antibody’s heavy chain, has the independent ability to bind with antigens. It contributes to antibody fragment formation as the critical antigen-binding region and is often used singularly or fused with other molecules to form compact, stable, high-affinity therapeutic or diagnostic antibodies. For example, in May 2024, Zai Lab Limited, a pharmaceutical company based in China, began a global Phase 2 clinical trial to assess the effectiveness and safety of ZL-1102. The latter is a new human VH antibody fragment (Humabody) targeting IL-17 and is under development as a topical therapy for mild-to-moderate chronic plaque psoriasis, aiming to enhance treatment accuracy and cut down systemic side effects and immunogenic reactions.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/antibody-fragments-global-market-report
Which Countries Are Leading the Antibody Fragments Market?
North America was the largest region in the antibody fragments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23307
This Report Delivers Insight On:
1. How big is the antibody fragments market, and how is it changing globally?
2. Who are the major companies in the antibody fragments market, and how are they performing?
3. What are the key opportunities and risks in the antibody fragments market right now?
4. Which products or customer segments are growing the most in the antibody fragments market?
5. What factors are helping or slowing down the growth of the antibody fragments market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
